Adamis Pharmaceuticl (NQ: ADMP )
0.1159 -0.0041 (-3.42%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Headline News about Adamis Pharmaceuticl
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) rose 43.2% to $0.2097 in pre-market trading after jumping over 16% on Tuesday. Adamis Pharmaceuticals recently announced a review of strategic...
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 11, 2022
Adamis Pharmaceuticals Seeks Strategic Options, Including Sale
October 04, 2022
12 Health Care Stocks Moving In Monday's Intraday Session
October 03, 2022
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per...
Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy
September 21, 2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19...
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
September 12, 2022
Adamis Achieves Enrolment Target In Mid-Stage Covid-19 Study, Awaits Data Safety Monitoring Board Review Later This Month
September 12, 2022
Adamis Pharmaceuticals (NASDAQ: ADMP) announced that it has reached the initial planned enrollment target in the ongoing U.S. Phase 2/3 clinical trial investigating Tempol as a treatment for COVID-19.
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period...
Why Is Super Micro Computer Higher By More Than 13%? 42 Stocks Moving In Thursday's Mid-Day Session
July 21, 2022
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares jumped 364.3% to $23.22. The company offered shares at an expected price of $5.00 per share with an insider lock-up period of 180 days ending...
Blackberry Considers Alternative To Selling Catapults As Continuation Of Covid-19 Means More Room For Adamis Pharmaceuticals Corp.
June 01, 2022
As an alternative to the $600 million non-core intellectual asset transaction it had agreed to with Catapult IP Innovations, BlackBerry
Via Best Stocks
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following